Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Sustained effect of seralutinib on circulating biomarkers in the Torrey phase 2 open-label extension study

Monday, November 11, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The Torrey phase 2 open-label extension study demonstrated that seralutinib has a sustained effect on circulating biomarkers. This finding suggests that seralutinib may provide long-term benefits for patients suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The results are promising for future treatment strategies.
Price reaction · baseline $0.8582 (2024-11-11 close) · hit after-hours · 4 other GOSS headline(s) in the window, move may be shared
day 0 close · peak
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows sustained effects on biomarkers.
  • The study indicates potential for long-term benefits.
  • Positive implications for patients with PAH and PH-ILD.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Sustained effect of seralutinib on circulating biomarkers in the Torrey phase 2 open-label extension study
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is seralutinib used for?

Seralutinib is used for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

What were the results of the Torrey phase 2 study?

The study showed that seralutinib has a sustained effect on circulating biomarkers, indicating potential long-term benefits.

What is the significance of circulating biomarkers?

Circulating biomarkers help in assessing the effectiveness of treatments and the progression of diseases like PAH and PH-ILD.

Is seralutinib effective for long-term treatment?

Yes, the study suggests that seralutinib may provide long-term benefits for patients.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib phase 2 study PAH PH-ILD biomarkers
Last updated: Nov 11, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →